Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

June 22, 2015

News Industry News

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA®

November 09, 2014

News Industry News

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

March 24, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.